Nine analysts set USD 24.71 target for MeiraGTx stock

Published on 10/20/2026 at 20:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 321.43 million versus USD 0.70 million. MeiraGTx stock costs EUR 9.00 on October 20, 2026 at 10:12 p.m. CEST.

Analyst target and reporting date

Nine analysts held a Moderate Buy consensus and an average USD 24.71 target on October 2, 2026.
Second-quarter revenue reached USD 321.43 million versus a USD 0.70 million consensus.
MeiraGTx stock was trading at EUR 9.00 at Lang & Schwarz on October 20, 2026 at 10:12 p.m. CEST.
MeiraGTx is expected to report third-quarter results on November 12, 2026.

MGTX, KYG596651029, Illustration mit AI erstellt.

MeiraGTx Holdings plc (KYG596651029) had a Moderate Buy consensus from nine analysts and an average 12-month target of USD 24.71 on October 2, 2026, according to MarketBeat. The company also reported second-quarter revenue of USD 321.43 million against a USD 0.70 million consensus, while earnings per share reached USD 1.71 versus a consensus loss of USD 0.46, the same source said. The stock was trading at EUR 9.00 at Lang & Schwarz on October 20, 2026 at 10:12 p.m. CEST.

Revenue sets a high comparison

The second-quarter revenue figure was the strongest operating number available for MeiraGTx in the latest reporting period. MarketBeat said the company last reported on August 13, 2026, when revenue reached USD 321.43 million and earnings per share beat the consensus estimate by USD 2.17.

Nasdaq valuation stays measurable

On Nasdaq, MeiraGTx was quoted at USD 10.11 at 2:17 p.m. ET on October 20, 2026. Its market capitalization was USD 971.0 million, the price-to-earnings ratio was 14.23, and trading volume was 336,561 shares at that time. The 52-week range extended from USD 6.62 to USD 15.35.

What comes next for MeiraGTx?

MarketBeat listed November 12, 2026 as the expected reporting date for third-quarter results, with a conference call scheduled for November 13, 2026. Its published estimates call for third-quarter revenue of USD 6.95 million and a loss of USD 0.46 per share. These figures are estimates rather than reported results.

Pipeline and investor dates

MeiraGTx describes itself as a clinical-stage genetic medicines company with programs in Parkinson's disease, radiation-induced xerostomia and inherited retinal disease. Its investor materials also highlight two GMP viral-vector production facilities and a riboswitch platform aimed at regulating gene expression through oral small molecules, according to MeiraGTx.

The stock's investor picture therefore combines a USD 24.71 analyst target with a USD 971.0 million market value and an upcoming November reporting date.

The further course of trading is shown by the continuously updated real-time quote of MeiraGTx stock.